



HHS Public Access

Author manuscript

J Antibiot (Tokyo). Author manuscript; available in PMC 2016 November 21.

Published in final edited form as:

J Antibiot (Tokyo). 2017 January ; 70(1): 65–72. doi:10.1038/ja.2016.52.

Design, Synthesis and Microbiological Evaluation of Ampicillin Tetramic acid Hybrid Antibiotics

Philip T. Cherian¹, Aditi Deshpande^{2,ϕ}, Martin N. Cheramie^{1,ϕ}, David F. Bruhn¹, Julian G. Hurdle^{2,3}, and Richard E. Lee^{1,*}

¹Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, TN 38105, USA

²Institute of Biosciences and Technology, Texas A&M Health Science Center, Houston, Texas 77030, USA

³Department of Microbial and Molecular Pathogenesis, Texas A&M Health Science Center, College of Medicine, Bryan, Texas, 77807, USA

Abstract

Exploiting iron-uptake pathways by conjugating β -lactam antibiotics with iron-chelators such as catechol and hydroxamic acid is a proven strategy to overcome permeability-related resistance in Gram-negative bacteria. Since naturally occurring iron chelating tetramic acids have not been previously examined for this purpose, an exploratory series of novel ampicillin-tetramic acid hybrids that structurally resemble ureidopenicillins was designed and synthesized. The new analogs were evaluated for the ability to chelate iron and their MIC activities determined against a representative panel of clinically significant bacterial pathogens. The tetramic acid β -lactam hybrids demonstrated a high affinity to iron in the order of 10^{-30} M³. The hybrids were less active against Gram-positive bacteria. However, against Gram-negative bacteria, their activity was species dependent with several hybrids displaying improved activity over ampicillin against wild-type *Pseudomonas aeruginosa*. The anti-Gram-negative activities of the hybrids improved in the presence of clavulanic acid revealing that the tetramic acid moiety did not provide added protection against β -lactamases. Additionally, the hybrids were found to be efflux pump substrates as their activities markedly improved against pump-inactivated strains. Unlike the catechol and hydroxamic acid siderophore β -lactam conjugates, the activities of the hybrids did not improve under iron-deficient conditions. These results suggest that the tetramic acid hybrids gain permeability via different membrane receptors, or they are out competed by native bacterial siderophores with stronger affinities for iron. This study provides a foundation for the further exploitation of the tetramic acid moiety to achieve novel β -lactam anti-Gram-negative agents, providing that efflux and β -lactamase mediated resistance is addressed.

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms

richard.lee@stjude.org to whom all correspondence should be addressed.

^ϕThese authors contributed equally to this work.

Introduction

β -lactam antibiotics are the leading marketed drugs for the treatment of bacterial infections, but resistance to this class of agents is now common in both gram-positive and gram-negative pathogens [1, 2]. The underlying mechanisms of resistance include production of β -lactamases that hydrolyze the lactam ring, alterations within the penicillin-binding protein (PBP) binding site that reduce antibiotic affinity, changes in outer membrane permeability that decrease antibiotic uptake, and increased expression of efflux pumps that reduce target access [3]. Studies have shown that permeability-mediated resistance can be overcome by exploiting the iron-uptake pathways as a Trojan horse strategy to enter antibiotics into bacterial cells [4]. Bacteria assimilate iron by synthesizing and utilizing low molecular weight iron-chelating compounds called siderophores and these Fe^{3+} -siderophore complexes are recognized and actively transported into cells by siderophore receptors located in the outer membrane [5]. Iron uptake mechanisms are particularly active in hosts where freely available iron in tissue fluids is scarce. Hence, conjugating antibiotics to siderophores presents an attractive approach to promote the cellular uptake of antibiotics. This strategy has been successfully applied to improve the *in vitro* activity of ampicillin and amoxicillin against Gram-negatives, including *Pseudomonas aeruginosa* [6, 7]. Also, novel monobactam antibiotics containing a siderophoric motif were shown to utilize the iron-uptake pathway to enter cells; these compounds also display efficacy in animal models of Gram-negative infections [8–10].

The most common siderophores belong to three main classes: catecholates, hydroxamates, and α -hydroxycarboxylates [11]. Of these, the catecholates and hydroxamates have been widely explored in antibiotic drug discovery [12]. One iron chelator moiety that appears to be underutilized is the class of natural products known as tetramic acids. Tetramic acid motifs are found in a wide variety of pharmacologically active natural products, with many displaying antifungal and antibacterial activities [13–15]. Molecules bearing the tetramic acid core demonstrate diverse modes of action ranging from inhibition of cell wall [16] and RNA synthesis [17] and dissipation of the membrane potential [18]. The tetramic acid motif has the ability to interact with acid and metal binding enzymatic domains in essential bacterial drug targets [19, 20]. However, there are no marketed antibiotics containing the tetramic acid motif. The 3-carbonyl tetramic acids are strongly acidic with $\text{pK}_a \sim 2.3\text{--}3.5$, and they chelate a variety of metal ions such as Fe^{3+} , Zn^{2+} , Ca^{2+} , Mg^{2+} , and Cu^{2+} [21, 22]. Recently, the tetramic acid harzianic acid was described as a novel siderophore in *Trichoderma harzianum* [23]. Similarly, based on studies by Kauffman et al. it is thought that physiological degradation of the quorum sensing molecule N-acylhomoserine lactones (AHL) to a tetramic acid may play a role in iron acquisition by *P. aeruginosa* [24]. However, tetramic acid molecules are not generally well described as siderophores in pathogenic bacteria. While several known siderophore moieties have been applied in discovering siderophore-fused β -lactam antibiotics, there is a lack of literature examining the use of the tetramic acid motif for cellular drug uptake. Considering these factors, we sought to examine the prospect of applying the tetramic acids motif to improve cellular uptake of β -lactam antibiotics. We hypothesized that attaching a 3-acyltetramic acid moiety to β -lactam antibiotics could improve their activity by increasing permeability by exploiting the metal

ion-uptake pathways. Since ampicillin has been successfully linked to other siderophores, we tested our hypothesis herein by synthesizing an exploratory series of novel ampicillin-tetramic acid hybrids, similar in molecular shape to ureidopenicillins, and examined their antimicrobial activities.

Results and discussion

Design of ampicillin– tetramic acid hybrids

The amine terminal of ampicillin was selected for the attachment of the tetramic acid motif based on the structures of previously reported ampicillin-siderophore conjugates where catecholate siderophores were attached to this position through acylation [6, 7]. These conjugates contained more than one catechol moieties attached to ampicillin via linkers of varying lengths (Figure 1A). For our study, we decided to attach the tetramic acid directly to the amine terminal of ampicillin, which was inspired by the observation that this amine is acylated to form a urea in the ureidopenicillins, such as piperacillin. Ureidopenicillins show broad-spectrum activity against Gram-positive and Gram-negative bacteria including most notably *P. aeruginosa* [25–27]. It was also noted that an acidic center was also tolerated at this position, as replacement of the ampicillin amine by a carboxylate group produces carbenicillin. Carbenicillin displays significant Gram-negative coverage including strain dependent antipseudomonal activity [28, 29]. The tetramic acid core offers several potential positions for attachment to the ampicillin amine. The 3-position was selected for attachment of ampicillin for synthetic ease and overall pharmacophoric match [30, 31]. Accordingly, we designed ampicillin-tetramic acid hybrids in which ampicillin was linked to the 3-position of tetramic acid via a carboxamide (Figure 1B). This design combined the structural features of both ureidopenicillins and carbenicillin while introducing a chelating tetramic acid. Based on this design a small library of analogs was synthesized to study the structure-activity relationship (SAR) (Figure 2). The intermediate 3-methoxycarbonyl tetramic acids were synthesized from various amino acids creating diversity at the C5 and the N1-positions of the tetramic acid core. These structural modifications allowed us to explore the influence of different physiochemical parameters such as of size, shape, hydrophobicity, and polarity on the activity of the hybrids. The hybrids were synthesized as shown in Scheme 1. The NMR characterization of 3-carbonyl tetramic acids can be complicated due to their ability to undergo keto-enol tautomerism. A total of nine tautomers are possible, but typically only four enolic tautomers are observed in solution (Figure 3) [15]. These tautomers form two pairs of internal tautomers ($a \rightleftharpoons b$ and $c \rightleftharpoons d$) which are in rapid equilibrium and a pair of external tautomers ($ab \rightleftharpoons cd$) which is in slow equilibrium. The interconversion of the external tautomers is postulated to proceed via the β -triketo tautomer *e* [32]. The ratio of the tautomers observed during NMR analysis can be influenced by the solvent [33]. In our study, the NMR for all hybrid molecules were performed in MeOH-*d*₄ and they all displayed only one major tautomer, which is tautomer *a*.

Antimicrobial activity against gram-positive bacteria in Mueller-Hinton broth

In order to determine the antimicrobial potential of these hybrids, they were initially tested against a panel of gram-positive and gram-negative bacteria in cation-adjusted Mueller-Hinton broth, with below MICs being mean values of at least two replicates. In general,

against gram-positive bacteria (Table 1), the fusion of ampicillin with tetramic acid led to a moderate loss in potency. Nevertheless, several hybrids displayed good activity with low MICs (<0.2 – 6.25 µg/ml) against methicillin-sensitive *S. aureus* (MSSA), *Streptococcus pyogenes*, *S. pneumoniae* and *Bacillus anthracis* Sterne and *B. subtilis*. Against *Enterococcus faecalis* and methicillin-resistant *S. aureus* (MRSA), most hybrids had MICs >25 µg/ml. Previously, we reported that the antimicrobial activity of tetramic acids belonging to the membrane active reutericyclin class was influenced by hydrophobic substituents at the N1, C5, and 3-positions of the tetramic core and that the simple hydrophilic tetramic acid core alone did not possess measurable antibacterial activity (MICs > 200 µg/ml) against Gram-positive bacteria [18, 34]. In comparison, for tetramic acid-ampicillin hybrids, different substituents at the C5 and N1-positions on the tetramic core, irrespective of their size, shape, hydrophobicity, and polarity produced similar activity, and no clear SAR was observed. Additionally, the position of the substituent (C5 or N1) did not affect the activity, for e.g. **2746** and **2742** which have a methyl group at the C5 and N1-position respectively have comparable activity; similarly, **2745** and **2919** which have a phenyl group at the C5 and N1-positions respectively have comparable activity. The lack of SAR and loss of potency compared to ampicillin might suggest suboptimal binding of these hybrids with target PBPs; however, due to the chelating nature of tetramic acids, the possibility that these hybrids may be functioning via mechanism(s) unrelated to PBP binding cannot be ruled out. Since cytotoxicity is a concern for tetramic acid bearing molecules, such as some reutericyclins, we investigated this property in the ampicillin-tetramic acid hybrids [14, 34]. When tested against HeLa cells, the hybrids were non-toxic producing cytotoxicity values similar to other penicillin antibiotic controls (Supporting information, Table S1).

Antimicrobial activity against gram-negative bacteria in Mueller-Hinton broth

Compounds within the tetramic acid class (e.g. reutericyclins) are typically inactive against the Gram-negative test panel in Table 2 [15, 18, 34]. However, against the panel of type strains of gram-negative bacteria, fusion of ampicillin with tetramic acid produced variable effects against the different species (Table 2), with a general observed trend that some hybrids showed increased activity over ampicillin and carbenicillin, but were inferior to piperacillin for some key species. Best results were observed against *P. aeruginosa*, where the activities of the hybrids were 4–16 fold better than ampicillin (>200 µg/ml) and 2–8 fold over carbenicillin. The most active compounds **1903**, **2781**, and **3002** showed MIC of 12.5 µg/ml, which is 2-fold less active than piperacillin (6.25 µg/ml). Against *Acinetobacter baumannii*, the MICs ranged from 25–100 µg/ml, with the exception of **1905**, **2746**, and **2780** (> 200 µg/ml); the compounds were generally better than ampicillin and carbenicillin (100 µg/ml) but were at least 4-fold less active than piperacillin (6.25 µg/ml). Against *Klebsiella pneumoniae* the hybrids displayed weaker activities (> 200 µg/ml) compared to ampicillin (100 µg/ml), carbenicillin (50 µg/ml), and piperacillin (6.25 µg/ml). Several hybrids displayed low MICs against *Proteus mirabilis* (1.56–25 µg/ml) and were comparable to ampicillin (3.13 µg/ml) and carbenicillin (1.56 µg/ml) but inferior to piperacillin (0.19 µg/ml). Against the ampicillin-resistant *P. vulgaris*, **2744 - 45**, **2780 - 82**, and **2916 - 18** (6.25–12.5 µg/ml) displayed improved activities over ampicillin and carbenicillin (100 µg/ml) but these were not better than piperacillin (1.56 µg/ml). Against *Escherichia coli* BW25113, the most active hybrids were **2917**, **2918**, **2919**, and **3002** which had MICs of 6.25–12.5 µg/ml

that was either comparable to piperacillin (6.25 µg/ml) or slightly inferior to ampicillin (3.13 µg/ml). Other compounds in the series displayed MICs of 25–200 µg/ml, which was comparable to carbenicillin (100 µg/ml). In order to determine whether the introduction of tetramic acid rendered ampicillin more susceptible to exclusion via efflux pumps, we tested the compounds against an *E. coli* BW25113 strain that lacked *tolC* important part of the AcrAB–TolC multidrug efflux system. The hybrids displayed dissimilar MIC activities against both *E. coli* BW25113 and the TolC-deficient strain, suggesting that they are substrates for the TolC based efflux systems, such as the AcrAB–TolC pump. For instance, **2916** which has MIC of 50 µg/ml against *E. coli* BW25113 showed a significantly reduced MIC of 1.56 µg/ml in the TolC-deficient strain (Table 2). These shifts are also observed for piperacillin and carbenicillin. These results suggest that efflux is a key factor dictating the relative activities of compounds in the series.

Activity against gram-negative bacteria in the presence of clavulanic acid

In order to determine whether the activity of these hybrids is affected by β-lactamases, their activity was determined in the presence of sub-inhibitory levels of clavulanic acid (6 µg/ml; Table 3 and Supporting information, Table S2). In the presence of clavulanic acid, hybrids displayed improved activities against wild type *E. coli* BW25113 with MIC activities comparable to the isogenic strain lacking chromosomally encoded β-lactamase AmpC. Improvement in MIC activity was also observed against *P. aeruginosa* in the presence of clavulanic acid with many hybrid compounds showing activity in the 3.1–6.3 µg/ml range. Against *E. coli* ATCC 35218, expressing the TEM-1 β-lactamase, clavulanic acid improved the activity of piperacillin, ampicillin, and compounds in the series with the exception of **2742**, **2743** and **2746** (Supporting information, Table S2). For example, in the presence of clavulanic acid activities of **2781**, **2782**, and **2916** were 25 µg/ml compared to >200 µg/ml in its absence. However, both the hybrids and control drugs did not show any activity against a panel of organisms expressing multiple β-lactamases (e.g. CTX-M-14, KPC-3, and VIM-1) suggesting that they are substrates for these and likely other β-lactamases (Supporting information, Table S2).

Comparison of compound activities under iron-depleted media

Unlike laboratory media, iron is not freely available in the body [35]. Hence, testing of β-lactam-siderophore conjugates under iron-depleted conditions improves the activity of these agents due to their increased cellular uptake via siderophore transporters which are more highly expressed under these conditions [36]. This led us to explore if tetramic acid chelation of metal ions may alter cellular uptake and whether testing in iron-depleted Mueller-Hinton media could enhance their activity. We first confirmed that the compounds chelate ferric ion. The addition of iron (III) chloride to **2916** resulted in the formation of an intense red to brown color consistent with the formation of a tetramic acid – iron complex [37]. The stoichiometry of 3:1 tetramic acid: iron for the complex was determined by the continuous variation method [24, 38] (Supporting information, Figure S1). Next, we tested the activity of these hybrids in iron-deficient conditions with 2, 2'-bipyridyl (30 µg/ml) to increase the expression of siderophore transporters [39–41]. A significant increase in siderophore production was confirmed in the test media for *P. aeruginosa* and *E. coli* (Supporting information, Table S3), which suggests an increase in cognate siderophore

receptors and other transporters for iron uptake[36]. Under iron-depleted conditions, **2916** and other test compounds either showed no change in activities or exhibited only a 2–4-fold difference in activities (Table 4). The trend in the broth MICs for the compounds against *P. aeruginosa* and *E. coli* strains was also evident from agar diffusion tests (Supporting information, Table S4). It was hypothesized that bacterial siderophores with higher affinity than tetramic acids for iron might be limiting the activity of these hybrids. Thus, the apparent binding constant ($K_{d, app}$) of **2916** for iron (III) was measured as $0.55 \times 10^{-29} M^3$ by monitoring the loss of absorbance of **2916**-iron (III) complex at 460 nm in presence of increasing concentrations of EDTA (Supporting information, Figure S2), which is similar to the previously reported values for tetramic acids [24]. Since in this experiment iron affinity of bidentate chelating tetramic acids is being compared to hexadentate bacterial siderophores, the parameter pM was also calculated for the binding for comparative purposes [42]. The pM value is expressed as $-\log [Fe^{3+}]$, where $[Fe^{3+}]$ is the free iron concentration in the presence of $10^{-5} M$ total iron chelator and $10^{-6} M$ total Fe^{3+} at pH 7.4. A larger pM value indicates a more effective ligand under the given conditions. Using this equation, the pM for **2916** was calculated to be 20.3. Thus, although the tetramic acid hybrids ($K_d 0.55 \times 10^{-29} M^3$ and pM 20.3) may compete favorably with weak iron chelating siderophores, such as pyochelin ($K_d 10^{-5} M$ and pM 6) [43, 44], they will likely be outcompeted by siderophores with larger pM values, such as *P. aeruginosa* pyoverdine ($K_d 10^{-32} M$ and pM 27) [45, 46] or *E. coli* enterobactin ($K_d 10^{-52} M$ and pM 35.6) [42]. Further, the affinities of tetramic acid for the membrane receptors of siderophores and iron uptake transporters are unknown. To explore these hypotheses, we tested the hybrid compounds against *P. aeruginosa* and *E. coli* mutants in which siderophore receptors or siderophores were inactivated by single gene deletions. This data is presented in Tables S5 and S6. In summary, deletion on the TonB protein in both species did not influence the activity of compounds; TonB plays a key role in the periplasmic uptake of siderophores as it interacts with several siderophore receptors to provide energy for transport [47]. The loss of enterobactin biosynthesis protein (*entB*), the ferrienterobactin permease, and other iron transporters did not affect the activity of the compounds against *E. coli*. Similarly, against *P. aeruginosa* the loss of pyoverdine biosynthesis (*pvcA*) [48] and pyoverdine receptors (e.g. *fpvA*; *fpvB*) [49, 50] did not affect the activities of the compounds. Together this suggests that the activities of the compounds are not influenced by siderophore competition and point to an alternate mechanism of uptake. In light of the compounds appearing as substrates for efflux pumps, we determined if the efflux pump inhibitor CCCP could enhance the activity of compounds against *P. aeruginosa* and *E. coli*. CCCP dissipates the bacterial proton motive force, leading to the inhibition of several efflux pumps [51]. As shown in Table 4, the addition of CCCP also significantly improved the activities of the compounds by 2–8 fold against *P. aeruginosa* and 2–16 fold against *E. coli*.

Conclusions

Our strategy for improving the activity of the β -lactam antibiotic ampicillin by fusing its amine terminal with iron chelating tetramic acids produced compounds with weak to moderate antibacterial activities. Compounds in this series were identified with improved activity against *P. aeruginosa*. The *P. aeruginosa* quorum-sensing signal N-3-oxododecanoyl-L-homoserine degrades under physiological conditions to produce a tetramic acid. The role

of the rearranged tetramic acid product is not yet clear, but it has been proposed to play a function in iron acquisition [24]. Other β -lactams siderophores conjugates have been reported to utilize cognate siderophore receptors for entry through the outer Gram-negative membrane. However, tetramic acids are in a different chemical class to hydroxamates and catechols that are typically utilized in siderophore drug conjugates. These conjugates must be recognized by specific outer membrane receptors whose expression levels are highest when iron concentrations are low. The activity of the tetramic acids β -lactam hybrids was independent of media iron concentration and hence we speculate that they use a different receptor or porin to enter *P. aeruginosa*. Future elucidation of this receptor or uptake mechanism could lead to compounds that are optimized to gain entry into *P. aeruginosa* and other Gram-negative pathogens. In addition, key limitations of the current series include susceptibility to efflux pumps and inactivation by β -lactamases. These liabilities may be addressed through combinations with efflux pump or β -lactamase inhibitors combined with future chemical optimization of the tetramic acid- β -lactam hybrids. Our study provides the first description of tetramic acid- β -lactam hybrids and suggests that further studies are required to determine the mechanism of entry to the periplasmic space to fully explore the utility of tetramic acids as Trojan horses in overcoming outer-membrane permeability mediated resistance to β -lactam antibiotics.

Experimental procedure

Chemistry

Details for the preparation of the ampicillin-tetramic acid hybrids are provided in the Supporting information. Briefly, various amino acid methyl esters were first acylated with methyl malonyl chloride and this intermediate was cyclized under Lacey-Dieckmann condition to afford 3-methoxycarbonyl tetramic acids. Microwave heating of the 3-methoxycarbonyl tetramic acids with ampicillin in DMF at 100°C for three minutes followed by purification by reverse phase column chromatography afforded the ampicillin – tetramic acid hybrids in 6 – 67% yields. The final compounds were characterized by LC-MS, ¹³CNMR, and ¹HNMR. All reported compounds were 95% pure.

Biology

Determination of minimum inhibitory concentrations (MICs) in Mueller-Hinton media—The MICs of compounds were determined in Mueller-Hinton (MH) broth according to the Clinical Laboratory Standards Institute (CLSI), using the microbroth dilution method in 96-well round bottom plates. The bacterial inocula were prepared by growing colonies from MH agar in MH broth. The final test concentration of compounds ranged from 200-0.2 μ g/ml and bacterial inocula of 10⁵ CFU/ml. After incubation at 37°C for 18–20 hours the MICs were recorded as the lowest concentration of test compound inhibiting visual growth [34]. MICs were also determined in the presence of the β -lactamase inhibitor clavulanic acid (6 μ g/ml). MICs were performed in at least duplicate and the mean MIC is reported.

Determination of minimum inhibitory concentrations (MICs) in iron-depleted media—MICs in iron-depleted media were similarly determined with the following

exceptions. Firstly, bacteria were grown on MH agar containing 30 µg/ml 2,2'-bipyridyl that chelates ferric iron.[52] Bacterial inocula were then prepared by growing colonies in MH broth containing 2, 2'- bipyridyl (30 µg/ml) to mid-logarithmic phase. MICs were then perform as above, but using MH broth that contained 2, 2'- bipyridyl (30 µg/ml); to permit adequate iron chelation, the 2,2'- bipyridyl was added to broth at least 3 hours before setting up MIC test. The MICs were read after 18–20 hours as above. MICs under iron-replete conditions were also assessed in the presence of the proton pump inhibitor 50 µg/ml carbonyl cyanide m-chlorophenyl (CCCP). MICs were performed in at least duplicate and the mean MIC is reported.

Detection of siderophore production by CAS liquid assay—The increased production of siderophores in iron-depleted media was determined using the reported chrome azurol S assay (CAS) liquid assay [53]. The following organisms were used to test for siderophore production: *P. aeruginosa* PAO1 and *E. coli* strains BW25113. The CAS reagent was prepared by adding 10 mL of 10 mM ferric chloride in hydrochloric acid (100 mM) to 590 mL of a 1 mM of aqueous solution of CAS. The Fe-CAS solution was added to 400 mL of a 2 mM aqueous hexadecyl-trimethyl-ammonium bromide (HDTMA) to yield CAS-Fe-HDTMA. Bacteria were grown for 18–20 hours in MH broth with and without 2, 2'- bipyridyl (30µg/ml) and culture turbidity determined at 600 nm. Subsequently, supernatants were filtered through 0.2 µM PES membrane filters to remove bacteria. Supernatants (700 µl) were mixed with 350 µl of the CAS-Fe-HDTMA reagent, incubated in the dark for an hour and absorbance recorded at 630 nm. The relative percentage of siderophore production was then calculated based on changes in absorbance readings as previously reported [53]. Triplicate cultures were used and all data were normalized based on the turbidity of the corresponding cultures.

Cytotoxicity assay—The HeLa cell line was cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) in a humidified incubator (37°C, 5% CO₂). Cells were cultured to semi-confluence, trypsinized, and collected by centrifugation. Washed cells were resuspended in fresh DMEM at ~10⁶ cells/mL and dispensed into 96-well microtitre plates (100 µL/well). After overnight incubation at 37°C, compounds were added at two-fold serial dilutions of test compounds (512-0.2 µg/mL) and plates incubated for 48 hours. Cytotoxicity was evaluated using Promega CellTiter Glo[®] luminescence assay. IC₅₀ data were obtained from dose–response curves plotted using Graphpad prism 5.

Determination of antibiotic susceptibility by agar diffusion—The susceptibilities of bacteria to test compounds were also evaluated by the agar diffusion technique as described,[54] with minor changes. Briefly, bacteria was cultured in low-iron MH broth and 100 µl of a 10⁶ CFU/ml sample was spread onto MH agar that contained 2,2'- bipyridyl (30 µg/ml). The plates were allowed to dry, before antibiotics (50 µl; 0.2 mM) were added to wells that were prepared with a core borer (6.35 mm). The plates were incubated at 37°C overnight and the diameter of zone of inhibition was measured (mm).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Dr. Karen Bush at Indiana University, Bloomington for providing the β -lactamase producing bacterial strains. *E. coli* mutants were from the Keio Collection at The Coli Genetic Stock Center, Yale, Connecticut, U.S.A.; *P. aeruginosa* mutants were from the PA Two-Allele Library, Manoil Lab, University of Washington, Seattle, U.S.A. This work was funded by Grant 5R01AT006732 from the National Center for Complementary and Alternative Medicine at the National Institutes of Health, with additional funds from the American Lebanese Syrian Associated Charities (ALSAC), St Jude Children's Research Hospital.


References

1. WHO. Antimicrobial resistance: global report on surveillance. 2014.
2. CDC. Antibiotic Resistance Threats in the US. 2013
3. Rice LB. Mechanisms of resistance and clinical relevance of resistance to beta-lactams, glycopeptides, and fluoroquinolones. *Mayo Clin Proc.* 2012; 87(2):198–208. [PubMed: 22305032]
4. Ghosh A, et al. Iron transport-mediated drug delivery using mixed-ligand siderophore- β -lactam conjugates. *Chemistry & Biology.* 1996; 3(12):1011–1019. [PubMed: 9000006]
5. Guerinot ML. Microbial Iron Transport. *Annual Review of Microbiology.* 1994; 48(1):743–772.
6. Heinisch L, et al. Highly Antibacterial Active Aminoacyl Penicillin Conjugates with Acylated Bis-Catecholate Siderophores Based on Secondary Diamino Acids and Related Compounds. *Journal of Medicinal Chemistry.* 2002; 45(14):3032–3040. [PubMed: 12086488]
7. Ji C, Miller PA, PA MJ. Iron Transport-Mediated Drug Delivery: Practical Syntheses and In Vitro Antibacterial Studies of Tris-Catecholate Siderophore–Aminopenicillin Conjugates Reveals Selectively Potent Antipseudomonal Activity. *Journal of the American Chemical Society.* 2012; 134(24):9898–9901. [PubMed: 22656303]
8. Brown MF, et al. Pyridone-Conjugated Monobactam Antibiotics with Gram-Negative Activity. *Journal of Medicinal Chemistry.* 2013; 56(13):5541–5552. [PubMed: 23755848]
9. van Delden C, Page MG, Kohler T. Involvement of Fe uptake systems and AmpC beta-lactamase in susceptibility to the siderophore monosulfactam BAL30072 in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother.* 2013; 57(5):2095–2102. [PubMed: 23422914]
10. Russo TA, et al. In vivo and in vitro activity of the siderophore monosulfactam BAL30072 against *Acinetobacter baumannii*. *Journal of Antimicrobial Chemotherapy.* 2011; 66(4):867–873. [PubMed: 21393224]
11. Hider RC, Kong X. Chemistry and biology of siderophores. *Natural Product Reports.* 2010; 27(5): 637–657. [PubMed: 20376388]
12. Page MGP. Siderophore conjugates. *Annals of the New York Academy of Sciences.* 2013; 1277(1): 115–126. [PubMed: 23346861]
13. Mo X, Li Q, Ju J. Naturally occurring tetramic acid products: isolation, structure elucidation and biological activity. *RSC Advances.* 2014; 4(92):50566–50593.
14. Royles BJL. Naturally Occurring Tetramic Acids: Structure, Isolation, and Synthesis. *Chemical Reviews.* 1995; 95(6):1981–2001.
15. Schobert R, Schlenk A. Tetramic and tetronic acids: An update on new derivatives and biological aspects. *Bioorganic & Medicinal Chemistry.* 2008; 16(8):4203–4221. [PubMed: 18334299]
16. Zhu W, et al. Antibacterial drug leads targeting isoprenoid biosynthesis. *Proceedings of the National Academy of Sciences.* 2013; 110(1):123–128.
17. Pronin SV, et al. Chemical Synthesis Enables Biochemical and Antibacterial Evaluation of Streptolydigin Antibiotics. *Journal of the American Chemical Society.* 2011; 133(31):12172–12184. [PubMed: 21714556]
18. Cherian PT, et al. Chemical Modulation of the Biological Activity of Reutericyclin: a Membrane-Active Antibiotic from *Lactobacillus reuteri*. *Sci. Rep.* 2014; 4

19. Lee LV, et al. Biophysical Investigation of the Mode of Inhibition of Tetramic Acids, the Allosteric Inhibitors of Undecaprenyl Pyrophosphate Synthase. *Biochemistry*. 2010; 49(25):5366–5376. [PubMed: 20476728]
20. Lu J, et al. Structures of Kibdelomycin Bound to *Staphylococcus aureus* GyrB and ParE Showed a Novel U-Shaped Binding Mode. *ACS Chemical Biology*. 2014; 9(9):2023–2031. [PubMed: 24992706]
21. Lebrun M-H, et al. Complexation of the fungal metabolite tenuazonic acid with copper (II), iron (III), nickel (II), and magnesium (II) ions. *Journal of Inorganic Biochemistry*. 1985; 24(3):167–181. [PubMed: 4045446]
22. Steyn PS, Rabie CJ. Characterization of magnesium and calcium tenuazonate from *Phoma sorghina*. *Phytochemistry*. 1976; 15(12):1977–1979.
23. Vinale F, et al. Harzianic acid: a novel siderophore from *Trichoderma harzianum*. *FEMS Microbiology Letters*. 2013; 347(2):123–129. [PubMed: 23909277]
24. Kaufmann GF, et al. Revisiting quorum sensing: Discovery of additional chemical and biological functions for 3-oxo-N-acylhomoserine lactones. *Proc Natl Acad Sci U S A*. 2005; 102(2):309–314. [PubMed: 15623555]
25. Bush LM, Johnson CC. Ureidopenicillins and beta-lactam/beta-lactamase inhibitor combinations. *Infectious disease clinics of North America*. 2000; 14(2):409–433. [PubMed: 10829263]
26. Ferres H, Basker MJ, O'Hanlon PJ. Beta-lactam antibiotics. I Comparative structure-activity relationships of 6-acylamino-6-phenylpenicillanic acid derivatives and their 6-[D-alpha-acylamino-phenylacetamido] penicillanic acid analogues. *The Journal of Antibiotics*. 1974; 27(12):922–930. [PubMed: 4219783]
27. Ferres H, et al. Beta-lactam antibiotics. II Structure-activity relationships of 6-[alpha-(alpha-ureidoacylamino)acylamino] penicillanic acids. *The Journal of Antibiotics*. 1978; 31(10):1013–1022. [PubMed: 101499]
28. Knudsen ET, Rolinson GN, Sutherland R. Carbenicillin: a new semisynthetic penicillin active against *Pseudomonas pyocyanea*. *British Medical Journal*. 1967; 3(5557):75–78. [PubMed: 4961466]
29. Chadwick P. Effect of Carbenicillin on *Pseudomonas aeruginosa*. *Canadian Medical Association Journal*. 1969; 101(7):74–80.
30. Peukert S, et al. Design and structure-activity relationships of potent and selective inhibitors of undecaprenyl pyrophosphate synthase (UPPS): tetramic, tetronic acids and dihydropyridin-2-ones. *Bioorg Med Chem Lett*. 2008; 18(6):1840–1844. [PubMed: 18295483]
31. Folkes A, et al. Design, synthesis and in vitro evaluation of potent, novel, small molecule inhibitors of plasminogen activator inhibitor-1. *Bioorg Med Chem Lett*. 2002; 12(7):1063–1066. [PubMed: 11909718]
32. Nolte MJ, Steyn PS, Wessels PL. Structural investigations of 3-acylpyrrolidine-2,4-diones by nuclear magnetic resonance spectroscopy and X-ray crystallography. *Journal of the Chemical Society, Perkin Transactions*. 1980; 1:1057–1065.
33. Jeong Y-C, Moloney MG. Synthesis of and Tautomerism in 3-Acyltetramic Acids. *The Journal of Organic Chemistry*. 2011; 76(5):1342–1354. [PubMed: 21250713]
34. Yendapally R, et al. N-Substituted 3-Acetyltetramic Acid Derivatives as Antibacterial Agents. *Journal of Medicinal Chemistry*. 2008; 51(5):1487–1491. [PubMed: 18281930]
35. Ratledge C, Dover LG. Iron metabolism in pathogenic bacteria. *Annu Rev Microbiol*. 2000; 54:881–941. [PubMed: 11018148]
36. Zheng T, Nolan EM. Enterobactin-mediated delivery of beta-lactam antibiotics enhances antibacterial activity against pathogenic *Escherichia coli*. *J Am Chem Soc*. 2014; 136(27):9677–9691. [PubMed: 24927110]
37. Lebrun MH, et al. Relationships between the structure and the phytotoxicity of the fungal toxin tenuazonic acid. *Phytochemistry*. 1988; 27(1):77–84.
38. Renny JS, et al. Method of continuous variations: applications of job plots to the study of molecular associations in organometallic chemistry. *Angew Chem Int Ed Engl*. 2013; 52(46):11998–12013. [PubMed: 24166797]


39. Carpenter BM, Whitmire JM, Merrell DS. This is not your mother's repressor: the complex role of fur in pathogenesis. *Infect Immun*. 2009; 77(7):2590–2601. [PubMed: 19364842]
40. Ji C, Miller PA, Miller MJ. Iron transport-mediated drug delivery: practical syntheses and in vitro antibacterial studies of tris-catecholate siderophore-aminopenicillin conjugates reveals selectively potent antipseudomonal activity. *J Am Chem Soc*. 2012; 134(24):9898–9901. [PubMed: 22656303]
41. Brown MF, et al. Pyridone-conjugated monobactam antibiotics with gram-negative activity. *J Med Chem*. 2013; 56(13):5541–5552. [PubMed: 23755848]
42. Carrano CJ, Raymond RN. Ferric Ion Sequestering Agents. 2. Kinetics and Mechanism of Iron Removal from Transferrin by Enterobactin and Synthetic Tricatechols. *J Am Chem Soc*. 1979; 101:5401–5404.
43. Cox CD, Graham R. Isolation of an iron-binding compound from *Pseudomonas aeruginosa*. *Journal of Bacteriology*. 1979; 137(1):357–364. [PubMed: 104968]
44. Zheng T, Nolan EM. Siderophore-based detection of Fe(III) and microbial pathogens. *Metallomics*. 2012; 4(9):866–880. [PubMed: 22854844]
45. Meyer JM, Abdallah MA. The Fluorescent Pigment of *Pseudomonas fluorescens*: Biosynthesis, Purification and Physicochemical Properties. *Microbiology*. 1978; 107(2):319–328.
46. Albrecht-Gary A-M, et al. Bacterial Iron Transport: Coordination Properties of Pyoverdine PaA, a Peptidic Siderophore of *Pseudomonas aeruginosa*. *Inorganic Chemistry*. 1994; 33(26):6391–6402.
47. Adams H, et al. Interaction of TonB with the outer membrane receptor FpvA of *Pseudomonas aeruginosa*. *J Bacteriol*. 2006; 188(16):5752–5761. [PubMed: 16885443]
48. Drake EJ, Gulick AM. Three-dimensional structures of *Pseudomonas aeruginosa* PvcA and PvcB, two proteins involved in the synthesis of 2-isocyano-6,7-dihydroxycoumarin. *J Mol Biol*. 2008; 384(1):193–205. [PubMed: 18824174]
49. Edgar RJ, et al. Interactions between an anti-sigma protein and two sigma factors that regulate the pyoverdine signaling pathway in *Pseudomonas aeruginosa*. *BMC Microbiol*. 2014; 14:287. [PubMed: 25433393]
50. Ghysels B, et al. FpvB, an alternative type I ferripyoverdine receptor of *Pseudomonas aeruginosa*. *Microbiology*. 2004; 150(Pt 6):1671–1680. [PubMed: 15184553]
51. Lomovskaya O, et al. Identification and characterization of inhibitors of multidrug resistance efflux pumps in *Pseudomonas aeruginosa*: novel agents for combination therapy. *Antimicrob Agents Chemother*. 2001; 45(1):105–116. [PubMed: 11120952]
52. Mochizuki H, et al. Bactericidal activity of M14659 enhanced in low-iron environments. *Antimicrob Agents Chemother*. 1988; 32(11):1648–1654. [PubMed: 2978112]
53. Dale SE, et al. Role of siderophore biosynthesis in virulence of *Staphylococcus aureus*: identification and characterization of genes involved in production of a siderophore. *Infect Immun*. 2004; 72(1):29–37. [PubMed: 14688077]
54. Wencewicz TA, et al. Trihydroxamate siderophore-fluoroquinolone conjugates are selective sideromycin antibiotics that target *Staphylococcus aureus*. *Bioconjug Chem*. 2013; 24(3):473–486. [PubMed: 23350642]

A



Bis-catecholate - ampicillin conjugate


Heinisch et al. 2001




Tris-catecholate - ampicillin conjugate

Ji et al. 2012


B




Ampicillin




Piperacillin



Carbenicillin



3-acyl tetramic acid



Ampicillin - Tetramic acid hybrid

Figure 1.

A. Structures of catecholate-based siderophore-ampicillin conjugates. B. Design of ampicillin - tetramic acid hybrids inspired by piperacillin and carbenicillin.




Figure 2.
Structures of ampicillin – tetramic acid hybrids





Figure 3.
Tautomerism of 3-carbonyl tetramic acids

**Scheme 1.**

Synthesis of ampicillin – tetramic acid hybrids. Reagents and conditions: a)TEA/DCM

b)NaOMe/MeOH c)ampicillin/DMF/MW/100°C/3mins

Table 1

MIC ($\mu\text{g/ml}$) of ampicillin-tetramic acid hybrids against gram-positive bacteria.

Compound	EF	SPy	SP	BA	BS	MSSA	MRSA
ampicillin	3.13	<0.2	<0.2	<0.2	<0.2	<0.2	50
piperacillin	3.13	<0.2	<0.2	0.39	0.39	<0.2	25
carbenicillin	3.13	<0.2	<0.2	<0.2	<0.2	<0.2	6.25
1903	25	0.39	0.39	3.13	1.56	0.78	25
1905	50	0.78	<0.2	3.13	3.13	0.78	50
1940	25	0.78	0.78	3.13	3.13	1.56	25
2742	25	1.56	1.56	6.25	3.13	1.56	100
2743	12.5	<0.2	<0.2	0.78	0.78	0.78	25
2744	12.5	0.78	0.39	6.25	3.13	1.56	25
2745	12.5	0.78	0.39	6.25	3.13	0.78	25
2746	25	0.39	0.39	1.56	3.13	1.56	50
2780	25	0.78	0.39	1.56	0.78	0.39	50
2781	25	0.39	<0.2	3.13	0.78	<0.2	25
2782	6.25	0.78	0.39	3.13	1.56	0.39	12.5
2833	12.5	0.78	<0.2	1.56	0.39	<0.2	25
2835	25	0.78	<0.2	3.13	<0.2	<0.2	25
2916	25	0.39	<0.2	1.56	1.56	<0.2	50
2917	25	0.39	<0.2	3.13	1.56	0.78	50
2918	25	1.56	0.39	6.25	3.13	0.78	50
2919	25	0.78	<0.2	3.13	1.56	0.78	50
3002	25	0.39	0.39	3.13	1.56	0.78	50

Key: EF= *E. faecalis* ATCC33186; SPy= *S. pyogenes* ATCC700294; SP= *S. pneumoniae* R6; BA= *B. anthracis* steme; BS= *B. subtilis* ATCC23857; MSSA= *S. aureus* -ATCC29213; MRSA= *S. aureus* NRS 70.

Table 2

MIC ($\mu\text{g/ml}$) of ampicillin-tetramic acid hybrids against gram-negative bacteria.

Compound	AB	EC	EC <i>tolC</i>	PV	PM	KP	PA
ampicillin	100	3.13	3.13	100	3.13	100	>200
piperacillin	6.25	6.25	1.56	1.56	0.19	6.25	6.25
carbenicillin	100	100	0.09	100	1.56	50	100
1903	50	50	6.25	25	12.5	200	12.5
1905	200	25	6.25	50	25	200	25
1940	100	50	12.5	50	6.25	>200	25
2742	100	100	12.5	100	6.25	>200	25
2743	50	200	12.5	100	3.13	>200	25
2744	100	100	3.13	12.5	12.5	>200	25
2745	50	100	3.13	12.5	3.13	>200	25
2746	200	200	12.5	100	3.13	>200	50
2780	>200	200	6.25	12.5	1.56	>200	25
2781	50	100	3.13	6.25	3.13	>200	12.5
2782	25	25	1.56	12.5	12.5	>200	25
2833	25	100	3.13	100	6.25	200	25
2835	50	100	3.13	25	25	200	25
2916	50	50	1.56	6.25	6.25	>200	25
2917	50	12.5	6.25	6.25	3.1	>200	25
2918	100	6.25	6.25	6.25	6.25	>200	50
2919	25	12.5	3.13	25	50	200	50
3002	50	6.25	3.13	25	1.56	200	12.5

Key: AB= *A. baumannii* ATCC 19606; EC= *E. coli* BW25113; EC *tolC*= *E. coli* BW25113 *tolC* derivative JW5503-1; PV= *P. vulgaris* ATCC 33420; PM= *P. mirabilis* ATCC 25933; KP= *K. pneumoniae* ATCC 13883; PA= *P. aeruginosa* PA01.

Table 3

MIC ($\mu\text{g/ml}$) of ampicillin-tetramic acid hybrids against gram-negative bacteria in presence of clavulanic acid.

Compounds clavulanic acid ($\mu\text{g/ml}$)	EC		KP		EC <i>ampC</i>		PA	
	+	-	+	-	+	-	+	-
ampicillin	1.56	3.13	25	100	1.56	3.13	100	>200
piperacillin	3.13	6.25	6.25	6.25	1.56	1.56	3.13	6.25
1903	12.5	50	25	200	1.56	6.25	6.25	12.5
1905	12.5	25	100	200	12.5	25	12.5	25
1940	12.5	50	25	>200	6.25	12.5	12.5	25
2742	25	100	100	>200	12.5	25	12.5	25
2743	12.5	200	25	>200	6.25	12.5	12.5	25
2744	25	100	25	>200	12.5	25	25	25
2745	12.5	100	25	>200	6.25	6.25	25	25
2746	50	200	>200	>200	25	50	25	50
2780	50	200	25	>200	3.13	12.5	12.5	25
2781	6.25	100	50	>200	3.13	6.25	3.13	12.5
2782	3.13	25	50	>200	3.13	6.25	12.5	25
2833	12.5	100	100	200	6.25	12.5	6.25	25
2835	6.25	100	100	200	12.5	50	6.25	25
2916	12.5	50	100	>200	3.13	6.25	6.25	25
2917	12.5	12.5	50	>200	12.5	25	6.25	25
2918	12.5	6.25	50	>200	6.25	25	6.25	50
2919	50	12.5	100	200	6.25	12.5	12.5	50
3002	6.25	6.25	25	200	6.25	6.25	3.13	12.5

Key: EC= *E. coli* BW25113; KP= *K. pneumoniae* ATCC 13883; PA= *P. aeruginosa* PA01; EC *ampC*– *E. coli* BW25113 *ampC* derivative JW4111-2. Clavulanic acid MICs were 100 $\mu\text{g/ml}$ against EC and KP; 200 $\mu\text{g/ml}$ against PA; and 25 $\mu\text{g/ml}$ against EC *ampC*.

MIC ($\mu\text{g/ml}$) of ampicillin-tetramic acid hybrids against *P. aeruginosa* and *E. coli* in the presence of carbonyl cyanide *m*-chlorophenyl hydrazone and 2, 2'-bipyridyl.

Table 4

	PA			EC			EC <i>tolC</i>					
	MH	MH+CCCP	MH+BP	MH+BP/CCCCP	MH	MH+CCCP	MH+BP	MH+BP/CCCCP	MH	MH+CCCP	MH+BP	MH+BP/CCCCP
Ampicillin	>200	>200	>200	12.5	3.13	1.56	3.13	0.78	3.13	1.56	3.13	0.39
Piperacillin	6.25	3.13	6.25	3.13	12.5	6.25	1.56	0.78	0.09	0.09	0.09	0.09
Carbencillin	200	25	50	1.56	6.25	12.5	6.25	0.78	1.56	0.78	0.56	0.78
1903	12.5	3.13	12.5	1.56	50	25	50	12.5	6.2	1.56	1.56	3.13
1905	25	3.13	6.25	0.78	25	12.5	12.5	6.25	6.25	1.56	1.56	0.78
1940	25	12.5	12.5	6.25	50	25	25	12.5	12.5	6.25	3.13	1.56
2742	25	12.5	12.5	6.25	100	50	100	12.5	12.5	6.25	6.25	1.56
2743	25	6.25	12.5	3.13	200	25	50	12.5	12.5	3.13	6.25	1.56
2744	25	12.5	50	25	100	25	50	25	3.13	1.56	3.13	0.78
2745	25	12.5	50	12.5	100	12.5	50	12.5	3.13	1.56	1.56	0.78
2746	50	12.5	50	12.5	200	12.5	100	12.5	12.5	3.13	6.25	1.56
2780	25	6.25	25	6.25	200	25	50	25	6.25	3.13	6.25	3.13
2781	12.5	3.13	6.25	1.56	100	25	25	3.13	3.13	1.56	3.13	1.56
2782	25	12.5	25	12.5	25	25	12.5	3.13	1.56	1.56	3.13	1.56
2833	25	12.5	25	12.5	100	50	50	6.25	3.13	1.56	1.56	0.78
2835	25	12.5	25	12.5	100	25	25	12.5	3.13	1.56	1.56	0.78
2916	25	12.5	25	6.25	50	25	25	12.5	1.56	0.78	1.56	0.78
2917	25	6.25	25	12.5	50	25	25	12.5	3.13	1.56	3.13	1.56
2918	50	6.25	25	6.25	200	12.5	25	6.25	1.56	0.78	1.56	0.78
2919	50	25	50	12.5	100	100	100	25	6.25	3.13	3.13	1.56
3002	12.5	6.25	12.5	3.13	6.25	1.56	3.13	1.56	3.13	1.56	3.13	0.78

Key: MH= Mueller-Hinton (MH) broth; MH+CCCP= MH broth containing 50 $\mu\text{g/ml}$ carbonyl cyanide *m*-chlorophenyl hydrazone (CCCP); MH+BP= MH broth containing 30 $\mu\text{g/ml}$ 2, 2'-bipyridyl; MH+BP/CCCCP= MH broth containing 30 $\mu\text{g/ml}$ 2, 2'-bipyridyl and 50 $\mu\text{g/ml}$ carbonyl cyanide *m*-chlorophenyl hydrazone. PA= *P. aeruginosa* PA01; EC= BW25113; EC *tolC*= *E. coli* BW25113 *tolC* derivative JW5503-1.